AiCuris Anti-infective Cures AG, a leading pharmaceutical company focused on infectious diseases, has announced that it has received a €15 million milestone payment from its licensing partner MSD following the European Medicines Agency’s (EMA) approval of its antiviral agent, PREVYMIS, for the prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk. This milestone payment triggers further potential milestone payments and royalties on future net sales. The funds obtained will be used to support the clinical development of AiCuris’ product candidate, Pritelivir, for the treatment of resistant herpes simplex virus (HSV) infections in immunocompromised patients.
The approval of PREVYMIS for the prophylaxis of CMV disease in adult kidney transplant recipients at high risk is a significant milestone for AiCuris. Larry Edwards, CEO of AiCuris, expressed excitement about the approval and stated that it is an important step towards providing a novel and effective treatment option for immunocompromised patients in need. PREVYMIS, initially approved in the United States in 2017 and the European Union in 2018 for the prophylaxis of CMV infection in adult recipients of allogeneic hematopoietic stem cell transplantation, has now expanded its indications with this latest approval.
With the milestone payment received and the potential for further payments and royalties, AiCuris aims to continue its research and development efforts in order to deliver new therapeutic options to immunocompromised patients with high medical needs. The company’s lead product, PREVYMIS, has demonstrated its efficacy in clinical trials and is now poised to make a significant impact in the prevention and treatment of CMV disease in high-risk patients.
